Target Price | $18.00 |
Price | $17.24 |
Potential |
4.41%
register free of charge
|
Number of Estimates | 4 |
4 Analysts have issued a price target Core Laboratories NV 2026 .
The average Core Laboratories NV target price is $18.00.
This is
4.41%
register free of charge
$24.00
39.21%
register free of charge
$14.00
18.79%
register free of charge
|
|
A rating was issued by 5 analysts: 0 Analysts recommend Core Laboratories NV to buy, 2 to hold and 3 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Core Laboratories NV stock has an average upside potential 2026 of
4.41%
register free of charge
|
Dec '24 |
2025 Estimates |
|
---|---|---|
Revenue Million $ | 523.85 | 535.29 |
2.76% | 2.18% | |
EBITDA Margin | 12.13% | 16.02% |
11.09% | 32.03% |
5 Analysts have issued a sales forecast Core Laboratories NV 2025 . The average Core Laboratories NV sales estimate is
This results in the following potential growth metrics:
5 Analysts have issued an Core Laboratories NV EBITDA forecast 2025. The average Core Laboratories NV EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
Dec '24 |
2025 Estimates |
|
---|---|---|
Earnings Per Share $ | 0.66 | 1.00 |
16.46% | 51.52% | |
P/E | 17.33 | |
EV/Sales | 1.81 |
Based on analysts' sales estimates for 2025, the Core Laboratories NV stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of
This results in the following potential growth metrics and future valuations:
Core Laboratories NV...
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.